Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

IF 41.9 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2026-05-07 DOI:10.1200/JCO-26-01027

Patrick Y Wen, Donald A Berry, Meredith B Buxton, Howard Colman, John de Groot, Michael Lim, Ingo Mellinghoff, James R Perry, Michael Weller, Nicholas A Blondin, Omar H Butt, Denise M Damek, Macarena I de la Fuente, Jan Drappatz, Erin Dunbar, Pierre Giglio, Emma Viktoria Hyddmark, Fabio Iwamoto, Kurt A Jaeckle, Lyndon Kim, Heather M Kling, Eudocia Q Lee, Megan Mantica, Tom Mikkelsen, Burt Nabors, Herbert B Newton, Jeffrey J Olson, David Schiff, Tobias Walbert, Shiao-Pei Weathers, Timothy Cloughesy, Andrew B Lassman

引用次数: 0

查看原文本刊更多论文

更正：评价瑞非尼在新诊断和复发的胶质母细胞瘤：GBM AGILE II/III期贝叶斯随机平台试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.